Stanford Discovers "Natural Ozempic" Peptide That Cuts Appetite 50% Without GI Side Effects

A team led by Katrin Svensson, assistant professor of pathology at Stanford Medicine, has identified a naturally occurring peptide that suppresses appetite as effectively as semaglutide in animal models — without the gastrointestinal side effects that cause millions of patients to discontinue GLP-1 drugs.

The peptide, named BRP (BRINP2-related peptide), is a 12-amino-acid fragment produced by enzymatic cleavage from a larger protein called BRINP2 (BMP/retinoic acid inducible neural specific 2). The study was published in Nature, with Laetitia Coassolo as lead author.

The discovery method is as significant as the peptide itself. The Stanford team built a computational tool called Peptide Predictor that systematically scanned all 20,000 human protein-coding genes to identify where prohormones — inactive precursor proteins — could be cleaved into smaller biologically active fragments. The algorithm identified 373 potentially active prohormones and screened approximately 100 candidate peptide molecules for effects on appetite-regulating neurons. BRP emerged as the strongest candidate from this AI-driven screen.

This is noteworthy because traditional drug discovery for obesity has focused on known hormonal pathways (GLP-1, GIP, glucagon). The Stanford approach asked a fundamentally different question: what undiscovered peptides does the human body already produce that regulate appetite? The answer was BRP — a peptide that had never been characterized before this study.

The animal results are striking, though they come with the standard caveat that animal data frequently fails to translate to humans.

Acute feeding suppression. A single intramuscular BRP injection administered before feeding reduced food intake by up to 50% within one hour. This effect was observed in both lean mice and minipigs — the fact that it replicated in a larger mammalian species is encouraging for translational potential, since minipig metabolism is more similar to human metabolism than mouse metabolism.

Chronic weight loss in obese mice. When obese mice received daily BRP injections for 14 days, they lost an average of 3 grams of body weight, primarily from fat. Control mice gained approximately 3 grams over the same period. The 6-gram net difference is substantial in a mouse model.

No observable side effects. Unlike GLP-1 agonists, BRP did not appear to cause nausea, vomiting, or digestive changes in the animal models. The researchers specifically measured movement, water intake, anxiety-like behavior, and gastric motility — all were unchanged. This is a direct contrast with semaglutide, which causes GI symptoms in 25–35% of human users and leads to treatment discontinuation in roughly 5–7% of patients.

Fat-specific weight loss. The weight reduction in obese mice was primarily from fat tissue rather than lean mass. If this selectivity were to hold in humans, it would address one of the most significant concerns about current GLP-1 therapy — the 25–40% lean mass loss that accompanies weight reduction on semaglutide and tirzepatide. However, this has not been tested in humans and should be interpreted cautiously.

The most scientifically important aspect of BRP is that it works through an entirely different mechanism than any existing weight loss drug. Understanding this explains why it may avoid GLP-1 side effects.

The GLP-1 pathway (semaglutide, tirzepatide). Current GLP-1 drugs activate GLP-1 receptors found throughout the body — in the brain, gut, pancreas, and other tissues. This widespread receptor activation explains both the benefits (appetite suppression, blood sugar control) and the side effects (nausea, vomiting, slowed gastric emptying, potential pancreatitis risk). The GI side effects are essentially an on-target consequence of activating gut-based GLP-1 receptors.

The BRP pathway. BRP activates POMC (pro-opiomelanocortin) neurons specifically in the hypothalamus — the brain region that serves as the central command center for appetite regulation. POMC neurons are the body's natural "satiety signal" neurons. When activated, they release alpha-MSH, which binds melanocortin-4 receptors (MC4R) and suppresses appetite.

BRP achieves this activation through an unidentified Gαs-coupled G-protein-coupled receptor (GPCR), triggering an intracellular signaling cascade: cAMP → PKA → CREB → FOS. This is a well-characterized signaling pathway in neuroscience, but the specific receptor that BRP binds has not yet been identified — a significant gap in the current understanding.

Why the pathway matters clinically. Because BRP acts specifically on hypothalamic neurons rather than on gut receptors, it may avoid the GI side effects that limit GLP-1 therapy. It also does not appear to slow gastric emptying — the mechanism by which GLP-1 drugs interact with oral contraceptives and other medications. If this targeted action profile holds in humans, it could offer appetite suppression without the tolerability issues that cause 5–7% of GLP-1 users to discontinue treatment.

The AI methodology behind this discovery may prove more important than BRP itself, because it opens a systematic approach to finding new therapeutic peptides.

The traditional approach. Historically, peptide hormone discovery has been serendipitous — researchers stumble on biologically active peptides through observational studies or targeted hypothesis testing. GLP-1 was discovered in the 1980s through research on gut hormones. GIP was identified through studies of incretin effects. Each discovery took decades of accumulated investigation in a specific biological system.

The Peptide Predictor approach. The Stanford team took an unbiased, genome-wide approach. Peptide Predictor analyzed more than 2,600 previously uncharacterized human proteolytic peptide fragments — pieces of proteins that are enzymatically cut from larger precursors but whose biological activity had never been studied. The algorithm predicted which fragments were likely to be biologically active based on cleavage site patterns, sequence conservation, and structural features.

Scale of the screen. From 20,000 protein-coding genes, Peptide Predictor identified 373 potentially active prohormones and approximately 100 candidate peptides with potential appetite-regulating activity. BRP was identified from this candidate pool through functional screening in neuronal cell cultures, then validated in animal models. This approach could theoretically be applied to any biological function — not just appetite — suggesting that many undiscovered bioactive peptides exist in the human genome.

The broader implication. If the human genome contains dozens or hundreds of undiscovered bioactive peptides — each with distinct receptor targets and signaling pathways — the current peptide therapy landscape may represent only a small fraction of what is biologically possible. The Stanford team's Peptide Predictor is essentially a tool for systematically mapping this hidden peptide biology.

The "natural Ozempic" framing in media coverage invites a direct comparison. Here is an honest assessment of where BRP stands relative to GLP-1 agonists.

Where BRP looks promising. In animal models, BRP matches semaglutide's appetite suppression without causing GI side effects, without slowing gastric emptying, and potentially without causing lean mass loss. If these properties hold in humans, BRP would address the three most significant limitations of current GLP-1 therapy.

Where GLP-1 drugs are far ahead. Semaglutide has been studied in more than 20,000 patients across multiple Phase 3 programs (STEP, SUSTAIN, PIONEER, SELECT, EVOKE). Tirzepatide has been studied in more than 10,000 patients across SURMOUNT and SURPASS programs. These drugs have 5+ years of real-world post-marketing safety data. BRP has been tested in mice and minipigs only. The evidence gap is enormous.

The translation problem. The history of drug development is filled with compounds that showed spectacular results in animal models and failed in humans. Reasons include differences in metabolism, receptor expression, blood-brain barrier penetration, immune response, and dosing pharmacokinetics. Approximately 90% of drugs that enter Phase 1 human trials never reach FDA approval. BRP's animal results are promising but represent the very beginning of a long development process.

What BRP cannot replace. Even if BRP succeeds in human trials, it addresses only appetite suppression. GLP-1 agonists have demonstrated cardiovascular benefits (SELECT trial), glycemic control, potential MASH/liver disease benefits, and kidney protective effects. These multi-system benefits arise precisely because GLP-1 receptors are distributed throughout the body. BRP's hypothalamus-specific action may avoid side effects but also limits its therapeutic scope.

The combination possibility. Some researchers have speculated that BRP could eventually be used in combination with lower-dose GLP-1 therapy — using BRP for central appetite suppression while using reduced-dose semaglutide for metabolic and cardiovascular benefits, potentially with fewer GI side effects. This is purely theoretical at this stage.

The media coverage has generated enormous public interest, but the timeline from animal discovery to prescription drug is measured in years, not months.

Current stage: preclinical. BRP has completed proof-of-concept studies in mice and minipigs. No human data of any kind exists — no pharmacokinetics, no safety profile, no dose-finding, no efficacy measurement.

Next step: human clinical trials. Katrin Svensson, the senior author, has co-founded a company to pursue human clinical trials. The first step would be a Phase 1 trial testing BRP safety and pharmacokinetics in a small number of healthy volunteers. This typically takes 12–18 months from first dosing.

The full development path. Assuming no failures: Phase 1 safety (1–2 years), Phase 2 dose-finding and initial efficacy (2–3 years), Phase 3 pivotal trials (2–3 years), FDA review (1–2 years). Total: approximately 6–10 years from Phase 1 initiation.

Realistic availability estimate. Under optimistic assumptions — rapid Phase 1 enrollment, positive results at every stage, fast-track FDA designation — BRP could potentially reach the market around 2032–2034. Under typical drug development timelines, 2035 or later is more realistic. And the most statistically likely outcome is that BRP will fail at some stage of human testing, because most drug candidates do.

What to do in the meantime. BRP is not an alternative to currently available treatments. Patients who would benefit from GLP-1 therapy should not delay treatment based on the possibility of a future drug. Semaglutide and tirzepatide are available now, have extensive safety data, and produce meaningful clinical outcomes. BRP is a scientific discovery, not a treatment option.

Setting aside the "natural Ozempic" headlines, this study has genuine scientific significance for three reasons.

It demonstrates that undiscovered appetite-regulating peptides exist. Before this study, the major appetite-regulating peptide pathways were thought to be well-mapped — GLP-1, GIP, PYY, ghrelin, leptin, and the melanocortin system. BRP acts through an unidentified receptor, which means there are appetite-regulatory mechanisms in the human body that science has not yet characterized. This opens an entirely new research direction.

It validates AI-driven peptide discovery. Peptide Predictor represents a new methodology for drug discovery that could accelerate the identification of therapeutic peptides for many conditions — not just obesity. If the approach proves reproducible, other research groups will apply similar tools to discover peptides relevant to inflammation, neurodegeneration, pain, and metabolic disease.

It expands the concept of peptide therapy. The current peptide therapy landscape is dominated by synthetic analogs of known hormones — semaglutide mimics GLP-1, tirzepatide mimics GLP-1 and GIP, PT-141 mimics alpha-MSH. BRP suggests that the next generation of peptide drugs may come from discovering endogenous peptides that the body already produces, rather than engineering synthetic mimics of known hormones. This is a philosophical shift in how peptide drugs are developed.

For PeptideMark readers, the takeaway is to watch for the Phase 1 trial announcement — that will be the first real test of whether BRP's animal promise translates to human biology. Until then, the "natural Ozempic" label is aspirational rather than evidence-based.